Law360 has named Lieff Cabraser partner Brendan Glackin a “Titan of the Plaintiffs Bar” for 2021. The publication selected 11 plaintiffs’ attorneys, “heavyweights in the fields of antitrust, securities and class action law…as well as champions of diverse legal theories holding corporations accountable and protecting the rights of consumers.”
The “Titans of the Plaintiffs Bar” awards recognize lawyers who “not only excel in the courtroom in large-scale litigation, but also take on leadership roles at their firms.” In-depth profiles of each chosen attorney will roll out over the next few weeks.
Congratulations to Brendan on this outstanding accomplishment!
About Brendan P. Glackin
The Chair of Lieff Cabraser’s Antitrust practice group, San Francisco office partner Brendan P. Glackin has represented direct purchasers of titanium dioxide in a nationwide antitrust class action lawsuit ($163.5 million in settlements); direct purchasers of flat-panel TV screens in litigation against the world’s leading LCDs manufacturers for conspiring to fix prices ($470 million in settlements; retailers in a monopolization pricing lawsuit against Abbott Laboratories charging that the company exploited the market for AIDS medicines used in conjunction with Abbott’s prescription drug Norvir, and employees in the high-tech workers class action alleging that major Silicon Valley firms colluded to reduce competition for workers.
Brendan has contributed groundbreaking work in litigation against drug makers for blocking access to affordable generics. This includes the blockbuster brand-name prescription drug Cipro ($399 million in settlements), which led to a 2016 “California Lawyer Attorney of the Year” (CLAY) award. Brendan continued his work in the field of generic drugs as lead counsel for Nashville General Hospital (the Hospital Authority of Metropolitan Government of Nashville) in a class-action antitrust case against defendants for monopolizing enoxaparin, the generic version of the blockbuster life-saving anti-coagulant Lovenox, which in 2019, settled for $120 million, the second largest indirect-purchaser antitrust pharmaceutical settlement fund in history, after Cipro.
He presently serves on the Lieff Cabraser team representing The Charles Schwab Corporation in the LIBOR manipulation suit.